3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Paclitaxel
19
pembrolizumab
16
Carboplatin
12
Bevacizumab
8
lenvatinib
6
rucaparib
5
Nivolumab
5
Megestrol Acetate
5
Radiation
4
Indocyanine Green
4
Gemcitabine
4
Cisplatin
4
tisotumab vedotin
3
temsirolimus
3
Sirolimus
3
Sentinel Lymph Node Biopsy
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
olaparib
2
niraparib
2
ixabepilone
2
iso-sulfan blue
2
irosustat
2
epacadostat
2
durvalumab
2
copanlisib
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Endometrial Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
No trials found.